| 0.81 -0.015 (-1.82%) | 04-24 13:33 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.14 | 1-year : | 1.28 |
| Resists | First : | 0.98 | Second : | 1.1 |
| Pivot price | 0.95  |
|||
| Supports | First : | 0.78 | Second : | 0.65 |
| MAs | MA(5) : | 0.84 |
MA(20) : | 0.96 |
| MA(100) : | 0.94 |
MA(250) : | 3.26 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 9.7 |
D(3) : | 4.7 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 10.89 | Low : | 0.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELOX ] has closed above bottom band by 17.9%. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.83 - 0.83 | 0.83 - 0.83 |
| Low: | 0.78 - 0.78 | 0.78 - 0.79 |
| Close: | 0.82 - 0.82 | 0.82 - 0.83 |
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.
Wed, 13 Mar 2024
Healthcare Stocks Moving Up and Down Wednesday: HRTX, ELOX, CRDF, CUE, TNON, TSVT, WORX, ADCT - InvestorsObserver
Wed, 13 Mar 2024
Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to License ZKN-013 for Rare Dermatological ... - Business Wire
Mon, 09 Oct 2023
Eloxx Pharmaceuticals (ELOX) Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients ... - StreetInsider.com
Tue, 11 Jul 2023
Why Eloxx Pharmaceuticals (ELOX) Stock Is Soaring Tuesday - Eloxx Pharmaceuticals (OTC:ELOX) - Benzinga
Mon, 10 Jul 2023
Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the ... - Yahoo Finance
Tue, 06 Jun 2023
Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 18.5 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 34 (K) |
| EPS | -8.89 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.54 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -73.3 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.13 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -18 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | -0.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.15 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|